Edition:
United States

Theravance Biopharma Inc (TBPH.OQ)

TBPH.OQ on NASDAQ Stock Exchange Global Market

25.32USD
3:59pm EST
Change (% chg)

$-1.68 (-6.22%)
Prev Close
$27.00
Open
$26.79
Day's High
$26.79
Day's Low
$25.27
Volume
86,977
Avg. Vol
64,159
52-wk High
$35.48
52-wk Low
$21.27

Chart for

About

Theravance Biopharma, Inc. is a biopharmaceutical company. The Company is engaged in creating medicines for patients suffering from serious illness. The Company operates in the segment of discovery (research), development and commercialization of human therapeutics. The Company's pipeline of internally discovered product... (more)

Overall

Beta: 1.81
Market Cap(Mil.): $1,496.10
Shares Outstanding(Mil.): 55.41
Dividend: --
Yield (%): --

Financials

  TBPH.OQ Industry Sector
P/E (TTM): -- 32.78 36.27
EPS (TTM): -4.72 -- --
ROI: -71.43 13.04 12.64
ROE: -295.61 14.06 13.67

Mylan and Theravance's COPD treatment gets FDA approval

Theravance Biopharma Inc and partner Mylan NV on Friday won U.S. regulatory approval for their treatment for a chronic lung condition that causes breathing-related problems.

Nov 09 2018

UPDATE 2-Mylan and Theravance's COPD treatment gets FDA approval

Nov 9 Theravance Biopharma Inc and partner Mylan NV on Friday won U.S. regulatory approval for their treatment for a chronic lung condition that causes breathing-related problems.

Nov 09 2018

Mylan and Theravance Biopharma's COPD treatment gets FDA approval

Nov 9 Theravance Biopharma Inc and partner Mylan NV on Friday won U.S. regulatory approval for their treatment for a chronic lung condition that causes breathing-related problems.

Nov 09 2018

Earnings vs. Estimates